Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives

Area of Science:

• Pediatric Rheumatology
• Immunology
• Rare Diseases

Background:

• Systemic juvenile idiopathic arthritis (SJIA) is a rare autoimmune condition with distinct systemic features.
• Advances in understanding SJIA immunopathogenesis have improved targeted therapies, but refractory disease persists.
• Refractory SJIA presents unique challenges and severe complications, necessitating further research.

Purpose of the Study:

• To review current treatment options for refractory SJIA.
• To explore potential future therapeutics for refractory SJIA.
• To propose a definition for refractory SJIA.

Main Methods:

• Literature review of existing and emerging SJIA therapies.
• Analysis of treatment outcomes for refractory SJIA subsets.
• Synthesis of proposed definition for refractory SJIA based on clinical criteria.

Main Results:

• Approximately 14% of SJIA patients are refractory to IL-1 or IL-6 inhibitors.
• A proposed definition for refractory SJIA includes active disease despite anti-IL-1/IL-6 therapy or prolonged glucocorticoid dependence.
• Management of SJIA complications like MAS, ILD, and amyloidosis varies and requires specialized approaches.

Conclusions:

• Refractory SJIA requires tailored treatment strategies beyond standard targeted therapies.
• Future research should focus on novel agents and combination therapies for refractory SJIA.
• Establishing a clear definition for refractory SJIA is crucial for consistent management and research.